Title | Beta cyclodextrins bind, stabilize, and remove lipofuscin bisretinoids from retinal pigment epithelium. |
Publication Type | Journal Article |
Year of Publication | 2014 |
Authors | Nociari MM, Lehmann GL, Bay AEPerez, Radu RA, Jiang Z, Goicochea S, Schreiner R, J Warren D, Shan J, de Beaumais SAdam, Ménand M, Sollogoub M, Maxfield FR, Rodriguez-Boulan E |
Journal | Proc Natl Acad Sci U S A |
Volume | 111 |
Issue | 14 |
Pagination | E1402-8 |
Date Published | 2014 Apr 08 |
ISSN | 1091-6490 |
Keywords | Animals, beta-Cyclodextrins, Binding Sites, Chromatography, High Pressure Liquid, Computer Simulation, Fluorescence, In Vitro Techniques, Lipofuscin, Mice, Mice, Knockout, Oxidation-Reduction, Retinal Pigment Epithelium, Retinoids |
Abstract | <p>Accumulation of lipofuscin bisretinoids (LBs) in the retinal pigment epithelium (RPE) is the alleged cause of retinal degeneration in genetic blinding diseases (e.g., Stargardt) and a possible etiological agent for age-related macular degeneration. Currently, there are no approved treatments for these diseases; hence, agents that efficiently remove LBs from RPE would be valuable therapeutic candidates. Here, we show that beta cyclodextrins (β-CDs) bind LBs and protect them against oxidation. Computer modeling and biochemical data are consistent with the encapsulation of the retinoid arms of LBs within the hydrophobic cavity of β-CD. Importantly, β-CD treatment reduced by 73% and 48% the LB content of RPE cell cultures and of eyecups obtained from Abca4-Rdh8 double knock-out (DKO) mice, respectively. Furthermore, intravitreal administration of β-CDs reduced significantly the content of bisretinoids in the RPE of DKO animals. Thus, our results demonstrate the effectiveness of β-CDs to complex and remove LB deposits from RPE cells and provide crucial data to develop novel prophylactic approaches for retinal disorders elicited by LBs.</p> |
DOI | 10.1073/pnas.1400530111 |
Alternate Journal | Proc Natl Acad Sci U S A |
PubMed ID | 24706818 |
PubMed Central ID | PMC3986126 |
Grant List | R21 EY022165 / EY / NEI NIH HHS / United States EY022165 / EY / NEI NIH HHS / United States R01 EY008538 / EY / NEI NIH HHS / United States P30 EY000331 / EY / NEI NIH HHS / United States EY08538 / EY / NEI NIH HHS / United States |